NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,422.51 mln
Float208 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
20.30
Exceptional upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.12
Very low leverage
ROE
-75.34
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Erasca is a San Diego-based company founded in 2018 that develops cancer treatments targeting a specific genetic pathway, known as RAS/MAPK, which drives the growth of many tumors. The company has several treatments in development, including therapies aimed at different mutations within this pathway, and works with a number of partners around the world to research, manufacture, and bring these treatments to market. Erasca's goal is to give patients with these hard-to-treat cancers more effective and precisely targeted options.
